HPC [ATTACH] ASX ANNOUNCEMENT 15 May 2025 ADVENT-AML Phase 1B...

HPC




ASX ANNOUNCEMENT 15 May 2025 ADVENT-AML Phase 1B clinical trial update

 Two of three evaluable patients have achieved CRi – Complete Response with incomplete blood count recovery (remission) in Acute Myeloid Leukemia (AML)

 This clinical trial is designed to enroll 20 newly diagnosed AML patients who are not eligible for chemotherapy or allogeneic stem cell transplant.

 Known as ADVENT-AML, the trial combines standard of care AML treatment with CHM’s CORENK technology to test a novel and potentially transformative new paradigm for AML patients

 ADVENT-AML is the first frontline AML trial to incorporate a cell therapy

Melbourne, Australia, 15 May 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”, is pleased to announce the ADVENT-AML Phase 1B clinical trial has 3 patients on frontline CHM CORE-NK protocol; 2 out of 3 patients have achieved CRi – Complete Response with incomplete blood count recovery. ADVENT-AML (www.clinicaltrials.gov/search?term=NCT05834244) is the first clinical trial to evaluate the synergy of Chimeric’s CHM CORE-NK technology in combination with the current standard of care for AML patients. The Phase 1B ADVENT-AML clinical trial at MD Anderson Cancer Centre has completed enrollement of relapsed/refractory AML subjects in the dose finding portion of the trial where no safety concerns were observed. In this second cohort of the phase 1b trial, newly diagnosed AML subjects who are elderly or otherwise unsuitable for transplantation and have not been previously treated for AML, will be eligible for enrollment. The third of the three patients achieved Stable Disease, whereby the cancer is neither increasing nor decreasing in extent or severity.